Reduced Sulfation of Chondroitin Sulfate but Not Heparan Sulfate in Kidneys of Diabetic db/db Mice

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 8, 2013, Pages 606-616

  Reine, Trine M ^a   Grøndahl, Frøy ^a   Jenssen, Trond G ^b,c   Hadler Olsen, Elin ^c   Prydz, Kristian ^a   Kolset, Svein O ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

Author keywords

chondroitin sulfate; diabetes; disaccharides; heparan sulfate; HPLC; immunohistochemistry; nephropathy; proteoglycan

Indexed keywords

4 O SULFATED DISACCHARIDE; 6 O SULFATED DISACCHARIDE; CARBOHYDRATE DERIVATIVE; CHONDROITIN 4 O SULFOTRANSFERASE; CHONDROITIN SULFATE; COLLAGEN TYPE 4; DERMATAN; DISACCHARIDE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HYALURONIC ACID; PERLECAN; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL DIABETES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SULFATION;

CHONDROITIN SULFATE; DIABETES; DISACCHARIDES; HEPARAN SULFATE; HPLC; IMMUNOHISTOCHEMISTRY; NEPHROPATHY; PROTEOGLYCAN;

ANIMALS; CHONDROITIN SULFATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; HEPARITIN SULFATE; KIDNEY; MICE; SULFATES;

EID: 84887378158     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413494392     Document Type: Article

References (42)

1. Allen TJ,Cooper ME,Lan HY.Use of genetic mouse models in the study of diabetic nephropathy.Curr Atheroscler Rep. 2004;6:197-202.
2. Bishop JR,Foley E,Lawrence R,Esko JD.Insulin-dependent diabetes mellitus in mice does not alter liver heparan sulfate.J Biol Chem. 2010;285:14658-14662.
3. Caterson B.Fell-Muir lecture: chondroitin sulphate glycosaminoglycans: fun for some and confusion for others.Int J Exp Pathol. 2012;93:1-10.
4. Celie JW,Reijmers RM,Slot EM,Beelen RH,Spaargaren M,Ter Wee PM,Florquin S,Van Den Born J.Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. Am J Physiol.Renal Physiol. 2008;294:F253-F263.
5. Chen S,Wassenhove-McCarthy DJ,Yamaguchi Y,Holzman LB,Van Kuppevelt TH,Jenniskens GJ,Wijnhoven TJ,Woods AC,McCarthy KJ.Loss of heparan sulfate glycosaminoglycan assembly in podocytes does not lead to proteinuria.Kidney Int. 2008;74:289-299.
6. Esko JD,Selleck SB.Order out of chaos: assembly of ligand binding sites in heparan sulfate.Annu Rev Biochem. 2002;71:435-471.
7. Farquhar MG,Wissig SL,Palade GE.Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall.J Exp Med. 1961;113:47-66.
8. Galeano B,Klootwijk R,Manoli I,Sun M,Ciccone C,Darvish D,Starost MF,Zerfas PM,Hoffmann VJ,Hoogstraten-Miller S,Krasnewich DM,Gahl WA,Huizing M.Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine.J Clin Invest. 2007;117:1585-1594.
9. Grøndahl F,Tveit H,Prydz K.Neutralization of endomembrane compartments in epithelial MDCK cells affects proteoglycan synthesis in the apical secretory pathway.Biochem J. 2009;418:517-528.
10. Hadler-Olsen E,Winberg JO,Reinholt FP,Larsen T,Uhlin-Hansen L,Jenssen T,Berg E,Kolset SO.Proteases in plasma and kidney of db/db mice as markers of diabetes-induced nephropathy.ISRN Endocrinol. 2011;2011:832642.
11. Hafstad AD,Khalid AM,How OJ,Larsen TS,Aasum E.Glucose and insulin improve cardiac efficiency and postischemic functional recovery in perfused hearts from type 2 diabetic (db/db) mice.Am J Physiol Endocrinol Metab. 2007;292:E1288-E1294.
12. Harvey SJ,Jarad G,Cunningham J,Rops AL,Van Der Vlag J,Berden JH,Moeller MJ,Holzman LB,Burgess RW,Miner JH.Disruption of glomerular basement membrane charge through podocyte-specific mutation of agrin does not alter glomerular permselectivity.Am J Pathol. 2007;171:139-152.
13. Jeansson M,Haraldsson B.Glomerular size and charge selectivity in the mouse after exposure to glucosaminoglycan-degrading enzymes.J Am Soc Nephrol. 2003;14:1756-1765.
14. Jeansson M,Haraldsson B.Morphological and functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier.Am J Physiol Renal Physiol. 2006;290:F111-F116.
15. Joladarashi D,Salimath PV,Chilkunda ND.Diabetes results in structural alteration of chondroitin sulfate/dermatan sulfate in the rat kidney: effects on the binding to extracellular matrix components.Glycobiology. 2011;21:960-972.
16. Kanwar YS,Danesh FR,Chugh SS.Contribution of proteoglycans towards the integrated functions of renal glomerular capillaries: a historical perspective.Am J Pathol. 2007;171:9-13.
17. Kanwar YS,Farquhar MG.Presence of heparan sulfate in the glomerular basement membrane.Proc Natl Acad Sci USA. 1979;76:1303-1307.
18. Kanwar YS,Linker A,Farquhar MG.Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion.J Cell Biol. 1980;86:688-693.
19. Kjellén L,Bielefeld D,Hook M.Reduced sulfation of liver heparan sulfate in experimentally diabetic rats.Diabetes. 1983;32:337-342.
20. Kjellén L,Lindahl U.Proteoglycans: structures and interactions.Annu Rev Biochem. 1991;60:443-475.
21. Kolset SO,Reinholt FP,Jenssen T.Diabetic nephropathy and extracellular matrix.J Histochem Cytochem. 2012;60:976-986.
22. Lauer ME,Hascall VC,Wang A.Heparan sulfate analysis from diabetic rat glomeruli.J Biol Chem. 2007;282:843-852.
23. Lawrence R,Lu H,Rosenberg RD,Esko JD,Zhang L.Disaccharide structure code for easy representation of constituent oligosaccharides from glycosaminoglycans.Nature Methods. 2008;5:291-292.
24. Ledin J,Ringvall M,Thuveson M,Eriksson I,Wilen M,Kusche-Gullberg M,Forsberg E,Kjellén L.Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not contribute to heparan sulfate N-sulfation.J Biol Chem. 2006;281:35727-35734.
25. Maccarana M,Sakura Y,Tawada A,Yoshida K,Lindahl U.Domain structure of heparan sulfates from bovine organs.J Biol Chem. 1996;271:17804-17810.
26. McCarthy KJ,Abrahamson DR,Bynum KR,St John PL,Couchman JR.Basement membrane-specific chondroitin sulfate proteoglycan is abnormally associated with the glomerular capillary basement membrane of diabetic rats.J Histochem Cytochem. 1994;42:473-484.
27. McCarthy KJ,Bynum K,St John PL,Abrahamson DR,Couchman JR.Basement membrane proteoglycans in glomerular morphogenesis: chondroitin sulfate proteoglycan is temporally and spatially restricted during development.J Histochem Cytochem. 1993;41:401-414.
28. Morita H,Yoshimura A,Inui K,Ideura T,Watanabe H,Wang L,Soininen R,Tryggvason K.Heparan sulfate of perlecan is involved in glomerular filtration.J Am Soc Nephrol. 2005;16:1703-1710.
29. Morita H,Yoshimura A,Kimata K.The role of heparan sulfate in the glomerular basement membrane.Kidney Int. 2008;73:247-248.
30. Raats CJ,Van Den Born J,Berden JH.Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria.Kidney Int. 2000;57:385-400.
31. Schaefer L.Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin.FASEB J. 2001;15:559-561.
32. Schumacher VA,Schlötzer-Schrehardt U,Karumanchi SA,Shi X,Zaia J,Jeruschke S,Zhang D,Pavenstaedt H,Drenckhan A,Amann K,Ng C,Hartwig S,Ng KH,Ho J,Kreidberg JA,Taglienti M,Royer-Pokora B,Ai X.WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier.J Am Soc Nephrol. 2011;22:1286-1296.
33. Shafat I,Ilan N,Zoabi S,Vlodavsky I,Nakhoul F.Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels.PLoS ONE. 2011;6:e17312.
34. Staatz WD,Toyoda H,Kinoshita-Toyoda A,Chhor K,Selleck SB.Analysis of proteoglycans and glycosaminoglycans from drosophila.Methods Mol Biol. 2001;171:41-52.
35. Steer DL,Shah MM,Bush KT,Stuart RO,Sampogna RV,Meyer TN,Schwesinger C,Bai X,Esko JD,Nigam SK.Regulation of ureteric bud branching morphogenesis by sulfated proteoglycans in the developing kidney.Dev Biol. 2004;272:310-327.
36. Unger E,Pettersson I,Eriksson UJ,Lindahl U,Kjellen L.Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats.J Biol Chem. 1991;266:8671-8674.
37. Utriainen A,Sormunen R,Kettunen M,Carvalhaes LS,Sajanti E,Eklund L,Kauppinen R,Kitten GT,Pihlajaniemi T.Structurally altered basement membranes and hydrocephalus in a type XVIII collagen deficient mouse line.Hum Mol Genet. 2004;13:2089-2099.
38. Van Den Born J,Pisa B,Bakker MA,Celie JW,Straatman C,Thomas S,Viberti GC,Kjellen L,Berden JH.No change in glomerular heparan sulfate structure in early human and experimental diabetic nephropathy.J Biol Chem. 2006;281:29606-29613.
39. Van Den Born J,Van Den Heuvel LP,Bakker MA,Veerkamp JH,Assmann KJ,Berden JH.A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats.Kidney Int. 1992;41:115-123.
40. Wijnhoven TJ,Van Den Hoven MJ,Ding H,Van Kuppevelt TH,Van Der Vlag J,Berden JH,Prinz RA,Lewis EJ,Schwartz M,Xu X.Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy.Diabetologia. 2008;51:372-382.
41. Xiong J,Wang Y,Zhu Z,Liu J,Zhang C,Hammes HP,Lang F,Feng Y.NG2 proteoglycan increases mesangial cell proliferation and extracellular matrix production.Biochem Biophys Res Commun. 2007;361:960-967.
42. Yard BA,Kahlert S,Engelleiter R,Resch S,Waldherr R,Groffen AJ,Van Den Heuvel LP,Van Der Born J,Berden JH,Kroger S,Hafner M,Van Der Woude FJ.Decreased glomerular expression of agrin in diabetic nephropathy and podocytes cultured in high glucose medium.Exp Nephrol. 2001;9:214-222.